['diabetes', 'diabetes mellitus, type 2']
['insulin 338 (gipet i)', 'insulin glargine', 'placebo']

        Inclusion Criteria:

          -  Age of 18-70 years (both inclusive) at the time of signing informed consent

          -  Body mass index of 25.0-40.0 kg/m^2 (both inclusive)

          -  Subject diagnosed (clinically) with type 2 diabetes mellitus for at least 180 days
             prior to the day of screening

          -  Insulin naïve subject; however, short term insulin treatment for a maximum of 14 days
             prior to the day of screening is allowed, as is prior insulin treatment for
             gestational diabetes

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to the trial products or related products

          -  Any disorder which in the investigator's opinion might jeopardise subject's safety or
             compliance with the protocol

          -  Presence of clinically significant gastrointestinal disorders potentially affecting
             absorption of drugs and/or nutrients, as judged by the investigator
      